| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
PURPOSE. To determine whether lacrimal and salivary gland nerves of an animal model of Sjögren’s syndrome, the MRL/lpr mouse, are able to release acetylcholine. The second purpose was to determine whether activation of the lacrimal gland nerves of the MRL/lpr mouse leads to protein secretion.
METHODS. Total saliva was collected for 10 minutes from the oral cavity of male and female MRL/lpr and MRL/+ mice, after intraperitoneal stimulation with pilocarpine and isoproterenol. Lacrimal and salivary gland lobules prepared from 18-week-old MRL/lpr and MRL/+ mice were incubated in the presence of depolarizing KCl (75 mM) solution. Acetylcholine release and peroxidase secretion (a protein secreted by the lacrimal gland) were measured using a spectrofluorometric assay.
RESULTS. Female, but not male, MRL/lpr mouse salivary glands were hyper-responsive to in vivo injection of secretagogues. These mice produced significantly higher amounts of saliva than did age-matched MRL/+ mice. Lacrimal and salivary gland nerves from 18-week-old MRL/+ mice released acetylcholine in response to a depolarizing KCl solution. In contrast, nerves in glands from 18-week-old MRL/lpr mice did not increase acetylcholine release in response to the depolarizing solution. Moreover, lacrimal glands from 18-week-old MRL/+ mice were able to secrete peroxidase in response to a depolarizing KCl solution, whereas those from 18-week-old MRL/lpr could not. This was not due to a defect in the secretory process, because addition of an exogenous secretagogue elicited peroxidase secretion from 18-week-old MRL/lpr as well as MRL/+ mice lacrimal glands.
CONCLUSIONS. The results show that activation of nerves of lacrimal and salivary glands infiltrated with lymphocytes does not increase the release of neurotransmitters, which results in impaired secretion from these glands.
This article has been cited by other articles:
|
|
 |
|
  D. S. Vinay, J. D. Kim, T. Asai, B. K. Choi, and B. S. Kwon Absence of 4 1BB Gene Function Exacerbates Lacrimal Gland Inflammation in Autoimmune-Prone MRL-Faslpr Mice Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4608 - 4615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Dias, C. M. Modulo, A. G. Jorge, A. M. Braz, A. A. Jordao Jr, R. B. Filho, J. S. de Paula, and E. M. Rocha Influence of Thyroid Hormone on Thyroid Hormone Receptor {beta}-1 Expression and Lacrimal Gland and Ocular Surface Morphology Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3038 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Dawson, P. C. Fox, and P. M. Smith Sjogrens syndrome--the non-apoptotic model of glandular hypofunction Rheumatology, July 1, 2006; 45(7): 792 - 798. [Full Text] [PDF]
|
|
|
|
|
|
M. Ramos-Casals and J. Font Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts Rheumatology, November 1, 2005; 44(11): 1354 - 1367. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Dawson, V. L. Caulfield, J. B. Stanbury, A. E. Field, S. E. Christmas, and P. M. Smith Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase Rheumatology, April 1, 2005; 44(4): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ding, B. Walcott, and K. T. Keyser Sympathetic Neural Control of the Mouse Lacrimal Gland Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1513 - 1520. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
